Terms: = Colorectal cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
1963 results:
1. Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic colorectal cancer.
Zhang XH; Zhou JQ; Wei Q; Li J; Xu T; Bai CM; Zhou JF; Wang XC
Discov Med; 2024 Jul; 36(186):1477-1485. PubMed ID: 39054718
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic implications of immunohistochemistry in patients with endometrial cancer.
Anca-Stanciu MB; Manu A; Olinca MV; Coroleucă BC; Comandaşu DE; Coroleucă CA; Maier C; Brătilă E
Rom J Morphol Embryol; 2024; 65(2):185-193. PubMed ID: 39020532
[TBL] [Abstract] [Full Text] [Related]
3. Dasabuvir alleviates 5-fluorouracil-induced intestinal injury through anti-senescence and anti-inflammatory.
He S; Wang Z; Xia J; Jia H; Dai Q; Chen C; He F; Wang X; Zhou M
Sci Rep; 2024 Jul; 14(1):15730. PubMed ID: 38977864
[TBL] [Abstract] [Full Text] [Related]
4. [Detection of PIK3CA gene mutation and its related prognosis in colorectal cancer based on next-generation sequencing].
Peng X; Zhang X; Lu HX; Shen LL; Gao N; Zan LK
Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):716-721. PubMed ID: 38955704
[No Abstract] [Full Text] [Related]
5. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status.
Zhang J; Zhou L; Zhao S; El-Deiry WS
Oncotarget; 2024 Jul; 15():424-438. PubMed ID: 38953895
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF
Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905
[TBL] [Abstract] [Full Text] [Related]
7. Impact of Oncogenic Changes in p53 and KRAS on Macropinocytosis and Ferroptosis in Colon cancer Cells and Anticancer Efficacy of Niclosamide with Differential Effects on These Two Processes.
Nguyen NT; Sennoune SR; Dharmalingam-Nandagopal G; Sivaprakasam S; Bhutia YD; Ganapathy V
Cells; 2024 May; 13(11):. PubMed ID: 38891084
[TBL] [Abstract] [Full Text] [Related]
8. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.
Michaeli O; Luz I; Vatarescu M; Manko T; Weizman N; Korotinsky Y; Tsitrina A; Braiman A; Arazi L; Cooks T
Cell Death Dis; 2024 Jun; 15(6):426. PubMed ID: 38890278
[TBL] [Abstract] [Full Text] [Related]
9. Cytotoxicity of alkaloids isolated from Peganum harmala seeds on HCT116 human colon cancer cells.
Salimizadeh Z; Enferadi ST; Majidizadeh T; Mahjoubi F
Mol Biol Rep; 2024 Jun; 51(1):732. PubMed ID: 38872006
[TBL] [Abstract] [Full Text] [Related]
10. Unlocking the potential of flavonoids: Natural solutions in the fight against colon cancer.
Hasibuan PAZ; Simanjuntak Y; Hey-Hawkins E; Lubis MF; Rohani AS; Park MN; Kim B; Syahputra RA
Biomed Pharmacother; 2024 Jul; 176():116827. PubMed ID: 38850646
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis).
Wang Z; Zhang X; Luo Y; Song Y; Xiang C; He Y; Wang K; Yu Y; Wang Z; Peng W; Ding Y; Liu S; Wu C
Cell Death Dis; 2024 May; 15(5):375. PubMed ID: 38811536
[TBL] [Abstract] [Full Text] [Related]
12. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J
Clin Transl Oncol; 2024 Aug; 26(8):1976-1987. PubMed ID: 38777950
[TBL] [Abstract] [Full Text] [Related]
13. Exploring active ingredients and mechanisms of Coptidis Rhizoma-ginger against colon cancer using network pharmacology and molecular docking.
Zeng T; Ling C; Liang Y
Technol Health Care; 2024; 32(S1):523-542. PubMed ID: 38759074
[TBL] [Abstract] [Full Text] [Related]
14. Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study.
Liu Y; Cui K; Ma W
Cancer Med; 2024 May; 13(9):e6910. PubMed ID: 38746969
[TBL] [Abstract] [Full Text] [Related]
15. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract] [Full Text] [Related]
16. Establishment of XRD fourier fingerprint identification method of realgar decoction pieces and its anti-tumor activity in tumor-in-situ transplanted mice.
Qian X; Wang Y; Liu Z; Fang F; Ma Y; Zhou L; Pan Y; Meng X; Yan B; Zhu X; Wang X; Zhao J; Liu S
J Ethnopharmacol; 2024 Sep; 331():118303. PubMed ID: 38734390
[TBL] [Abstract] [Full Text] [Related]
17. Distinct Driver Pathway Enrichments and a High Prevalence of
Tapia-Valladares C; Valenzuela G; González E; Maureira I; Toro J; Freire M; Sepúlveda-Hermosilla G; Ampuero D; Blanco A; Gallegos I; Morales F; Erices JI; Barajas O; Ahumada M; Contreras HR; González J; Armisén R; Marcelain K
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731914
[TBL] [Abstract] [Full Text] [Related]
18. Apoptotic effect of 5-fluorouracil-doxorubicin combination on colorectal cancer cell monolayers and spheroids.
Bilgin S
Mol Biol Rep; 2024 May; 51(1):603. PubMed ID: 38698270
[TBL] [Abstract] [Full Text] [Related]
19. The Relationship of Microsatellite Instability with BRAF and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
[TBL] [Abstract] [Full Text] [Related]
20. Exploring the Key Signaling Pathways and ncRNAs in colorectal cancer.
Lee YJ; Kim WR; Park EG; Lee DH; Kim JM; Shin HJ; Jeong HS; Roh HY; Kim HS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674135
[TBL] [Abstract] [Full Text] [Related]
[Next]
